Abstract |
The aim of this study was to evaluate the safety of zimeldine, a 5-HT reuptake inhibitor, in the long-term treatment of depressive disorders. The study was an open label, multicentre investigation involving 147 patients who were suffering from depressive illness and who needed long-term anti-depressant treatment. Sixty-five patients completed the intended treatment period of 1 year, 75 terminated prematurely, and 7 are still in the programme. The reasons for termination were mainly ineffectiveness of the drug and adverse reactions. During the long-term treatment the most common emergent symptoms were, in order of decreasing frequency, dizziness, dry mouth, sleep disorders, sweating, tremor, nausea and headache. The side-effects were, however, mild and they generally decreased during the treatment period. No new adverse symptoms were reported. In the long-term treatment group, body weight showed a slight mean decrease. Clinical chemistry and cardiovascular investigations were judged to show no changes of clinical importance. It is concluded that zimeldine was shown to be a safe drug in this 1-year treatment programme of depression.
|
Authors | J Wålinder, A Arberg-Wistedt, H Jozwiak, L von Knorring, C Nyström |
Journal | Acta psychiatrica Scandinavica. Supplementum
(Acta Psychiatr Scand Suppl)
Vol. 308
Pg. 147-60
( 1983)
ISSN: 0065-1591 [Print] Denmark |
PMID | 6230889
(Publication Type: Journal Article)
|
Chemical References |
- Zimeldine
- Creatinine
- Aspartate Aminotransferases
- Alanine Transaminase
- Alkaline Phosphatase
|
Topics |
- Adolescent
- Adult
- Aged
- Alanine Transaminase
(blood)
- Alkaline Phosphatase
(blood)
- Aspartate Aminotransferases
(blood)
- Body Weight
(drug effects)
- Child
- Creatinine
(blood)
- Depressive Disorder
(drug therapy)
- Electrocardiography
- Female
- Humans
- Male
- Middle Aged
- Nausea
(chemically induced)
- Sleep Wake Disorders
(chemically induced)
- Time Factors
- Zimeldine
(adverse effects)
|